美股行情约 15 分钟延迟,仅供参考
LLY礼来

医疗 · 制药

$1347.11-0.30%

最近行情 · 2026/11/22 05:00(北京时间)说明

礼来深度研究

了解本期变化、关键问题与接下来值得关注的事项。

最近检查公告:2026/11/21 21:14:50(北京时间)。

财务数据与报告期间

财务摘要 · 生物科技与医药研发

单季度资料截至 2026-09-30 · 披露 2026-10-29

内容更新 2026-11-08 · 最近核验 2026-11-16

超过日常核验窗口,以下保留上次可用版本。

本期净利润非负;是否具有持续性,还需要结合收入来源、现金流和一次性项目核查。

营业收入
243.97亿美元
2026-07-01 至 2026-09-30 · USD
净利润
64.51亿美元
2026-07-01 至 2026-09-30 · USD
现金及现金等价物
48.85亿美元
截至 2026-09-30 · USD
总资产
1,480.72亿美元
截至 2026-09-30 · USD
归属母公司股东权益
402.71亿美元
截至 2026-09-30 · USD

接下来关注什么

  • 核对临床进度、监管节点与项目失败风险;研发支出不能代替疗效证据。
  • 核对可用现金、融资约束与实际资金消耗,不能从单期亏损直接推算存续月份。
数据说明与暂缺项目
  • 经营现金流未取得本期同口径数据,不使用旧期替代。
  • 总负债未取得本期同口径数据,不使用旧期替代。
  • 现金流累计数未直接当作单季度;缺少可核对的单季值时留空。
  • 本页提供财务摘要,详细业务分析暂未提供。
最近定期披露与核对依据

披露日期不等于经营事件发生日;定期披露列表不代表已解释全部重大事项。

返回公司概览 →
新财报数据期 2026-09-30 · 研究更新 2026-10-29

营业收入 244亿美元;较前期变化 6.2%

毛利率 83.88%;较前期变化 -1.9 个百分点

接下来关注:Mounjaro + Zepbound 合计季度销售额

本期财务证据 · 2026-09-30

LLY:连续季度变化与现金流拆解

以下为已发布数据的规则比较,不是人工研究核查。公司整体数据不能替代产品、地区或客户指标;待验证不等于投资逻辑未变。

连续季度财务对照
指标FY2026 Q3FY2026 Q2环比
营业收入243.97亿美元229.74亿美元+6.2%
经营现金流113.97亿美元106.9亿美元+6.6%

横向滑动表格,查看上季数值和环比变化。

现金流变化如何拆解

缺少连续季度的现金流字段,暂不计算现金流变化归因。

关键研究问题

GLP-1 产能扩张速度(供给是否跟上需求)

仅有间接线索

资料截至 2026-09-30

间接证据:本期营收变动 6.2%,毛利率变动 -1.9 个百分点。该结果只描述“产品放量质量”,不能单独验证当前研究变量,因此不输出积极或负面结论。

产品放量质量:营收 6.2%;毛利率变动 -1.9 个百分点

继续关注:同一产品的出货、交付、产能或量产里程碑

暂未列出足以直接回答此问题的依据。

查看依据与尚未确认的问题

仅凭公司整体收入或毛利率尚不能回答此问题。

间接线索 · 3 份文件

客户与供应链 · 10-Q 审阅文档原文 · 3 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
客户与供应链 · 10-Q 审阅文档原文 · 4 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
客户与供应链 · 10-Q 审阅文档原文 · 1 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

背景资料 · 12 份文件

10-Q(提交于 2026-10-29) · 13 条摘录阅读原文 ↗
  • 2026 Q3:营收 24.40 十亿美元,毛利率 83.88%,自由现金流 未披露。
  • LLY 于 2026-10-29 提交 10-Q:截至 2026-09-30 的定期报告。
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • Acquired in-process research and development 4,181 656 7,541 2,381
  • Acquired in-process research and development 7,541 2,381
  • We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
  • We have a license agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • Acquisition date June 25, 2026 June 24, 2026 March 4, 2026
10-Q(提交于 2026-08-05) · 12 条摘录阅读原文 ↗
  • 2026 Q2:营收 22.97 十亿美元,毛利率 85.78%,自由现金流 未披露。
  • LLY 于 2026-08-05 提交 10-Q:截至 2026-06-30 的定期报告。
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • Acquired in-process research and development 2,776 154 3,360 1,726
  • Acquired in-process research and development 3,360 1,726
  • We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
  • We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
8-K 原始文件 · 1 条摘录阅读原文 ↗
  • LLY 于 2026-10-29 提交 8-K:经营业绩与财务状况、财务报表与附件。
SCHEDULE 13D 原始文件 · 5 条摘录阅读原文 ↗
  • LLY 于 2026-10-16 提交 SCHEDULE 13D:股东行动。
  • If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
  • The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.
  • The funds used by the Reporting Person to acquire the Common Stock purchased in the IPO consisted of cash on hand.
  • The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.
8-K 原始文件 · 1 条摘录阅读原文 ↗
  • LLY 于 2026-08-05 提交 8-K:经营业绩与财务状况、财务报表与附件。
并购交易 · SCHEDULE 13D 审阅文档原文 · 4 条摘录阅读原文 ↗
  • If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
  • The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.
  • The funds used by the Reporting Person to acquire the Promissory Note and the Common Stock purchased in the IPO consisted of cash on hand.
  • The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.
诉讼进展 · 10-Q 审阅文档原文 · 13 条摘录阅读原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of March 31, 2026, we have the right to receive up to $ 660 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
  • We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.
  • We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • In March 2026, we acquired all shares of Ventyx Biosciences, Inc. (Ventyx) for a purchase price of $ 14.00 per share in cash (or an aggregate of $ 1.1 billion, net of cash acquired).
  • Our access to information was limited prior to this acquisition.
诉讼进展 · 10-K 审阅文档原文 · 14 条摘录阅读原文 ↗
  • This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
  • We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.
  • See, for examples, Item 1A, "Risk Factors—Risks Related to Our Operations—Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could result in material harm to our business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."
  • A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.
  • The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.
  • Some of our products are subject to significant license and collaboration agreements.
  • For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 3: Collaborations and Other Arrangements."
  • The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.
  • Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.
  • For more information on patent challenges and litigation involving our intellectual property rights, see Item 1A, "Risk Factors—Risks Related to Our Intellectual Property—Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected" and Item 8, "Financial Statements and Supplementary Data—Note 16: Contingencies."
诉讼进展 · 10-Q 审阅文档原文 · 14 条摘录阅读原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Acquired in-process research and development (Note 3) 655.7 2,826.4 2,381.2 3,091.2
  • (1) As of September 30, 2025, there was $ 12.40 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
  • Acquired in-process research and development 2,381.2 3,091.2
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • In July 2025, we acquired all shares of Verve Therapeutics, Inc. (Verve) for a purchase price of $ 10.50 per share in cash (or an aggregate of approximately $ 549.4 million, net of cash acquired), plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $ 3.00 per share (or an aggregate of up to approximately $ 300 million) payable, subject to certain terms and conditions, upon the achievement of a certain specified milestone.
  • Our access to information was limited prior to this acquisition.
诉讼进展 · 10-Q 审阅文档原文 · 14 条摘录阅读原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Acquired in-process research and development (Note 3) 153.8 154.3 1,725.5 264.8
  • (1) As of June 30, 2025, there was $ 13.11 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
  • Acquired in-process research and development 1,725.5 264.8
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.
  • The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.
  • The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.
  • In May 2024, we acquired NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC, which together own the assets of a manufacturing site in Wisconsin, for a purchase price of $ 924.7 million, net of cash acquired.
  • The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
诉讼进展 · 10-Q 审阅文档原文 · 14 条摘录阅读原文 ↗
  • This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Acquired in-process research and development (Note 3) 1,571.7 110.5
  • (1) As of March 31, 2025, there was $ 13.80 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.
  • Acquired in-process research and development 1,571.7 110.5
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.
  • Upon each asset acquisition, the cost allocated to acquired in-process research and development (IPR&D) was immediately expensed as acquired IPR&D if the compound had no alternative future use.
  • Milestone payment obligations incurred prior to regulatory approval of the compound were expensed as acquired IPR&D when the event triggering an obligation to pay the milestone occurred.
  • We recognized acquired IPR&D charges of $ 1.57 billion and $ 110.5 million for the three months ended March 31, 2025 and 2024, respectively.
  • The acquired IPR&D charges for the three months ended March 31, 2025 were primarily related to the acquisition of Scorpion Therapeutics, Inc.'s (Scorpion's) PI3Kα inhibitor program STX-478, currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.
  • We recognized no other significant acquired IPR&D charges during the three months ended March 31, 2025 and 2024.
诉讼进展 · 10-K 审阅文档原文 · 14 条摘录阅读原文 ↗
  • This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.
  • issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;
  • litigation, investigations, or other similar proceedings involving past, current, or future products or activities;
  • Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
  • We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.
  • business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."
  • In recent periods, we have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.
  • A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.
  • The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.
  • Some of our products are subject to significant license and collaboration agreements.
  • For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 4: Collaborations and Other Arrangements."
  • The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.
  • Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.

保险覆盖范围扩大(影响市场可及性)

仅有间接线索

资料截至 2026-09-30

已有与该变量相关的公司披露线索,但尚不能直接证明该变量,暂不输出方向结论。

继续关注:公司正式披露、可定位且与变量同口径的经营 KPI

暂未列出足以直接回答此问题的依据。

查看依据与尚未确认的问题

仅凭公司整体财务指标或行业叙事尚不能回答此问题。

间接线索 · 3 份文件

客户与供应链 · 10-Q 审阅文档原文 · 3 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
客户与供应链 · 10-Q 审阅文档原文 · 4 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
客户与供应链 · 10-Q 审阅文档原文 · 1 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

口服 GLP-1(Orforglipron)临床进展(若成功将改变竞争格局)

仅有间接线索

资料截至 2026-09-30

已有与该变量相关的公司披露线索,但尚不能直接证明该变量,暂不输出方向结论。

继续关注:公司正式披露、可定位且与变量同口径的经营 KPI

暂未列出足以直接回答此问题的依据。

查看依据与尚未确认的问题

仅凭公司整体财务指标或行业叙事尚不能回答此问题。

间接线索 · 3 份文件

客户与供应链 · 10-Q 审阅文档原文 · 3 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
客户与供应链 · 10-Q 审阅文档原文 · 4 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;
  • litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;
  • We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
  • As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
客户与供应链 · 10-Q 审阅文档原文 · 1 条摘录阅读原文 ↗
  • issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

接下来检查什么

  1. Mounjaro + Zepbound 合计季度销售额
  2. 全年收入指引是否上调
  3. 产能扩张里程碑(新工厂批准情况)
更新记录与发布信息

数据期 2026-09-30 · 当前版本 2026-09-30.r1 · 本股发布 2026-11-21

  1. 2026-10-29 · 数据期 2026-09-30 · 2026-09-30.r1

    纳入截至 2026-09-30 的最新披露;0 个变量状态发生变化。

  2. 2026-08-05 · 数据期 2026-06-30 · 2026-06-30.r1

    纳入截至 2026-06-30 的最新披露;0 个变量状态发生变化。

  3. 2026-04-30 · 数据期 2026-03-31 · 2026-03-31.r1

    Tracker 规则更新;底层披露期未变化,不视为新的投资逻辑版本。

全部原始资料 · 12 份文件

同一份披露的摘录集中展示;背景资料不等于研究问题的直接依据。

10-Q(提交于 2026-10-29) · 16 条摘录阅读原文 ↗
2026-09-30 · 2026 Q3:营收 24.40 十亿美元,毛利率 83.88%,自由现金流 未披露。

SEC/XBRL 标准化字段;数据质量分 86。

2026-09-30 · LLY 于 2026-10-29 提交 10-Q:截至 2026-09-30 的定期报告。

已审阅正文并提取 14 条结构化披露。 提取结果保留原文并单独标注事实、展望或观点。

2026-10-29 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · Acquired in-process research and development 4,181 656 7,541 2,381

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · Acquired in-process research and development 7,541 2,381

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · We have a license agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-29 · Acquisition date June 25, 2026 June 24, 2026 March 4, 2026

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

10-Q(提交于 2026-08-05) · 16 条摘录阅读原文 ↗
2026-06-30 · 2026 Q2:营收 22.97 十亿美元,毛利率 85.78%,自由现金流 未披露。

SEC/XBRL 标准化字段;数据质量分 86。

2026-06-30 · LLY 于 2026-08-05 提交 10-Q:截至 2026-06-30 的定期报告。

已审阅正文并提取 14 条结构化披露。 提取结果保留原文并单独标注事实、展望或观点。

2026-08-05 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · Acquired in-process research and development 2,776 154 3,360 1,726

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · Acquired in-process research and development 3,360 1,726

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · As of June 30, 2026, we have the right to receive up to $ 410 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-08-05 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

8-K 原始文件 · 1 条摘录阅读原文 ↗
2026-10-29 · LLY 于 2026-10-29 提交 8-K:经营业绩与财务状况、财务报表与附件。

已审阅正文,未发现可由确定性规则结构化的重大经营信号。 提取结果保留原文并单独标注事实、展望或观点。

SCHEDULE 13D 原始文件 · 5 条摘录阅读原文 ↗
2026-10-16 · LLY 于 2026-10-16 提交 SCHEDULE 13D:股东行动。

已审阅正文并提取 4 条结构化披露。 提取结果保留原文并单独标注事实、展望或观点。

2026-10-16 · If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-16 · The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-16 · The funds used by the Reporting Person to acquire the Common Stock purchased in the IPO consisted of cash on hand.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-10-16 · The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

8-K 原始文件 · 1 条摘录阅读原文 ↗
2026-08-05 · LLY 于 2026-08-05 提交 8-K:经营业绩与财务状况、财务报表与附件。

已审阅正文,未发现可由确定性规则结构化的重大经营信号。 提取结果保留原文并单独标注事实、展望或观点。

并购交易 · SCHEDULE 13D 审阅文档原文 · 4 条摘录阅读原文 ↗
2026-07-30 · If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-07-30 · The name, business address, present principal occupation or employment and citizenship of each director and executive officer (including a director and officer who may be a controlling person) of the Reporting Person is set forth on Schedule A.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-07-30 · The funds used by the Reporting Person to acquire the Promissory Note and the Common Stock purchased in the IPO consisted of cash on hand.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-07-30 · The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis.

按确定性规则从 SEC SCHEDULE 13D 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

诉讼进展 · 10-Q 审阅文档原文 · 14 条摘录阅读原文 ↗
2026-04-30 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · As of March 31, 2026, we have the right to receive up to $ 660 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss, for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis, in Europe.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us the worldwide development and commercialization rights to orforglipron, which is branded and trademarked as Foundayo.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · In March 2026, we acquired all shares of Ventyx Biosciences, Inc. (Ventyx) for a purchase price of $ 14.00 per share in cash (or an aggregate of $ 1.1 billion, net of cash acquired).

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-04-30 · Our access to information was limited prior to this acquisition.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

诉讼进展 · 10-K 审阅文档原文 · 14 条摘录阅读原文 ↗
2026-02-12 · This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property;

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · See, for examples, Item 1A, "Risk Factors—Risks Related to Our Operations—Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could result in material harm to our business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · Some of our products are subject to significant license and collaboration agreements.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 3: Collaborations and Other Arrangements."

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2026-02-12 · For more information on patent challenges and litigation involving our intellectual property rights, see Item 1A, "Risk Factors—Risks Related to Our Intellectual Property—Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected" and Item 8, "Financial Statements and Supplementary Data—Note 16: Contingencies."

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

诉讼进展 · 10-Q 审阅文档原文 · 14 条摘录阅读原文 ↗
2025-10-30 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · Acquired in-process research and development (Note 3) 655.7 2,826.4 2,381.2 3,091.2

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · (1) As of September 30, 2025, there was $ 12.40 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · Acquired in-process research and development 2,381.2 3,091.2

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · In July 2025, we acquired all shares of Verve Therapeutics, Inc. (Verve) for a purchase price of $ 10.50 per share in cash (or an aggregate of approximately $ 549.4 million, net of cash acquired), plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $ 3.00 per share (or an aggregate of up to approximately $ 300 million) payable, subject to certain terms and conditions, upon the achievement of a certain specified milestone.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-10-30 · Our access to information was limited prior to this acquisition.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

诉讼进展 · 10-Q 审阅文档原文 · 14 条摘录阅读原文 ↗
2025-08-07 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · Acquired in-process research and development (Note 3) 153.8 154.3 1,725.5 264.8

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · (1) As of June 30, 2025, there was $ 13.11 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · Acquired in-process research and development 1,725.5 264.8

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · The results of operations of the acquisition are included in our consolidated condensed financial statements from the date of acquisition.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · In May 2024, we acquired NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC, which together own the assets of a manufacturing site in Wisconsin, for a purchase price of $ 924.7 million, net of cash acquired.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-08-07 · The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

诉讼进展 · 10-Q 审阅文档原文 · 14 条摘录阅读原文 ↗
2025-05-01 · This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · Acquired in-process research and development (Note 3) 1,571.7 110.5

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · (1) As of March 31, 2025, there was $ 13.80 billion remaining under our $ 15.00 billion share repurchase program authorized in December 2024.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · Acquired in-process research and development 1,571.7 110.5

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · Upon each asset acquisition, the cost allocated to acquired in-process research and development (IPR&D) was immediately expensed as acquired IPR&D if the compound had no alternative future use.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · Milestone payment obligations incurred prior to regulatory approval of the compound were expensed as acquired IPR&D when the event triggering an obligation to pay the milestone occurred.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · We recognized acquired IPR&D charges of $ 1.57 billion and $ 110.5 million for the three months ended March 31, 2025 and 2024, respectively.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · The acquired IPR&D charges for the three months ended March 31, 2025 were primarily related to the acquisition of Scorpion Therapeutics, Inc.'s (Scorpion's) PI3Kα inhibitor program STX-478, currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-05-01 · We recognized no other significant acquired IPR&D charges during the three months ended March 31, 2025 and 2024.

按确定性规则从 SEC 10-Q 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

诉讼进展 · 10-K 审阅文档原文 · 14 条摘录阅读原文 ↗
2025-02-19 · This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities;

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks;

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · litigation, investigations, or other similar proceedings involving past, current, or future products or activities;

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · business and reputation" and "Risk Factors—Risks Related to Litigation and Government Regulation—Regulatory compliance problems could be damaging to the company."

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · In recent periods, we have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · A specific use of a drug or biologic can receive "orphan" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · Some of our products are subject to significant license and collaboration agreements.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data—Note 4: Collaborations and Other Arrangements."

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

2025-02-19 · Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.

按确定性规则从 SEC 10-K 正文或附件提取的原文片段,未由 AI 改写;请结合上下文和公司原始文件复核。

继续关注这家公司

免费关注 LLY,方便下次继续研究

通过邮件登录后,将公司加入自选,并选择是否接收研究更新提醒。创建账户免费,不会自动扣费。

也可以使用 Google 或已有账户登录并关注。首次登录即创建免费账户。

加入自选方便下次继续阅读,邮件提醒需单独订阅。请留意各部分的报告期间,尚未确认的问题不代表已经发生。内容仅供研究参考,不构成投资建议。研究方法与限制

反馈